开发合并症指数以识别小肠出血患者中再出血及小肠血管疾病风险
本研究回顾性分析日本2家医院2003年6月至2016年7月404例经双气囊小肠镜确诊的小肠出血患者,构建Ohmiya合并症指数,并在88例前瞻性队列中验证。该指数识别小肠血管疾病的AUROC为0.7758,高于Charlson指数(0.6828)和ATRIA评分(0.6728)。指数≥2分者再出血风险比为1.729(95%CI 1.038-2.882,P=0.0355)。
要点
- Ohmiya指数识别小肠血管疾病的AUROC为0.7758,优于Charlson指数和ATRIA评分。
- 指数≥2分患者再出血风险比为1.729(95%CI 1.038-2.882,P=0.0355)。
- 指数结合发病年龄有助于区分Meckel憩室、克罗恩病、炎症性疾病、药物性损伤或肿瘤。
核心结论
- 基于合并症和小肠出血发病年龄构建的Ohmiya指数可识别再出血和血管疾病风险较高的患者。
研究设计与样本
- 回顾性分析日本2家医院2003年6月至2016年7月经双气囊小肠镜确诊的小肠出血患者404例,并在88例前瞻性队列中验证。
主要发现
- Ohmiya指数识别小肠血管疾病的AUROC为0.7758,高于Charlson指数0.6828(P<0.0001)和ATRIA评分0.6728(P<0.0001)。
- 在51例口服抗凝药患者中,Ohmiya评分AUROC为0.5254,与outcomes registry for better informed treatment评分0.5857相比无显著差异(P=0.4300)。
- 回顾性队列中,Ohmiya指数识别小肠血管疾病的敏感性为68%(93/137)、特异性为84%(223/267)、准确性为78%(316/404);验证队列中分别为63%(22/35)、85%(45/53)、76%(67/88)。
- 发病年龄<50岁且指数评分<2识别Meckel憩室和克罗恩病的准确性为53%;发病年龄≥50岁且指数评分<2识别炎症性疾病、药物性损伤或肿瘤的准确性为72%;指数评分≥2识别小肠血管疾病的准确性为68%,与年龄无关。
- Ohmiya指数评分≥2的患者中33%发生再出血,评分<2的患者中15%发生再出血(评分≥2的风险比为1.729;95%CI 1.038-2.882;P=0.0355)。
临床怎么用
- 作者认为,基于合并症和发病年龄的指数可识别再出血和血管疾病风险较高的患者,例如对小肠血管疾病行小肠镜下止血、对炎症性疾病行药物治疗、对肿瘤和憩室行手术并小肠镜标记。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We aimed to establish a comorbidity index for small bowel vascular diseases (SBVD) associated with small bowel bleeding (SBB) and recurrent bleeding. METHODS: We performed a retrospective analysis of 404 patients diagnosed with SBB via double-balloon enteroscopy, at 2 hospitals in Japan from June 2003 through July 2016. We collected data on comorbidities, computed Charlson Comorbidity Index and anticoagulation and risk factors in atrial fibrillation (ATRIA) scores, and analyzed associations with SBVD, rebleeding, and overall survival associated with bleeding and/or comorbidities. We used these data to develop a comorbidity index to identify patients at risk for SBVD, rebleeding, and reduced survival time. We validated our findings in a separate, prospective cohort of 88 patients with SBB. RESULTS: We developed a weighted index (the Ohmiya index) that identified patients who developed SBVD with an area under the receiver operating characteristic (AUROC) curve of 0.7758; this value was higher than that of the Charlson index score (0.6828; P < .0001) or ATRIA score (0.6728; P < .0001) alone. Among the 51 patients taking oral anticoagulants, there was no significant difference in AUROCs for the Ohmiya score (0.5254) vs the outcomes registry for better informed treatment score (0.5857; P = .4300). In the retrospective cohort, the Ohmiya index identified patients with SBVD with 68% sensitivity (93/137), 84% specificity (223/267), and 78% accuracy (316/404); in the validation cohort, these values were 63% (22/35), 85% (45/53), and 76% (67/88), respectively. Onset age <50 years and index score <2 identified patients with Meckel's diverticulum and Crohn's disease with 53% accuracy. Onset age ≥50 years and index score <2 identified patients with inflammatory diseases, drug-induced injuries, or tumors with 72% accuracy. An index score ≥2 identified patients with SBVD with 68% accuracy, regardless of age. Among patients with Ohmiya index scores ≥2, 33% had rebleeding; among patients with scores <2, 15% had rebleeding (hazard ratio for score ≥2, 1.729; 95% CI, 1.038-2.882; P = .0355). CONCLUSION: We developed an index, based on comorbidities and age of onset of SBB, that identified patients at risk for rebleeding and vascular disease (for example, enteroscopic hemostasis for SBVD, medication for inflammatory diseases, surgery with enteroscopic tattooing for tumors and diverticula). UMIN: 000025693.
引用
- Ohmiya N, Nakamura M, Osaki H, et al. Development of a Comorbidity Index to Identify Patients With Small Bowel Bleeding at Risk for Rebleeding and Small Bowel Vascular Diseases. Clin Gastroenterol Hepatol. 2018. PMID: 30130626. doi:10.1016/j.cgh.2018.08.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。